Navigation Links
Arena Pharmaceuticals Announces Fourth Quarter and Full Year 2007 Financial Results
Date:2/27/2008

ign, scope, enrollment and other aspects of current and planned clinical trials and other studies of Arena's or its collaborators' product candidates and compounds; the tolerability, side effects, efficacy and potential of Arena's or its collaborators' product candidates and compounds; the advancement of Arena's R&D efforts; the advancement and content of Arena's pipeline; Arena's collaborations, including expected activities thereunder; expectations relating to the agreements and Arena's relationship with Siegfried; lorcaserin's development, FDA submission and commercialization; financial guidance and assumptions, including relating to partnering and its series B preferred stock; and other statements about Arena's vision, outlook, strategy, preclinical and internal and partnered clinical programs, and ability to develop compounds and commercialize drugs. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, planned clinical trials and studies may not proceed at the time or in the manner Arena expects or at all, the results of preclinical studies or clinical trials may not be predictive of future results, Arena's ability to partner lorcaserin, APD125, APD791 or other of its compounds or programs, the timing, success and cost of Arena's research, out-licensing endeavors and clinical trials, Arena's ability to obtain additional financing, Arena's ability to obtain and defend its patents, the timing and receipt of payments and fees, if any, from Arena's collaborators, and Arena's ability to redeem with common stock any outstanding shares of its series B preferred stock. Additional factors that could cause actual results to differ materially from those stated or implied by Arena's forward-looking statements are disclos
'/>"/>
SOURCE Arena Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Arena Pharmaceuticals to Present at the Bear Stearns 20th Annual Healthcare Conference
2. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiogaphic Data Safety Monitoring Board Review
3. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiographic Data Safety Monitoring Board Review
4. Arena Pharmaceuticals Selected to Join New NASDAQ NeuroInsights Neurotech Index
5. Arena Pharmaceuticals to Present at Two Upcoming Investor Conferences
6. Arena Pharmaceuticals to Report Third Quarter 2007 Financial Results and to Host Conference Call and Webcast on Wednesday, October 17, 2007
7. Arena Pharmaceuticals Announces Third Quarter 2007 Financial Results
8. Arena Pharmaceuticals to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Arena Pharmaceuticals Appoints Phillip M. Schneider and Randall E. Woods to Board of Directors
10. Arena Pharmaceuticals Initiates Second and Third Pivotal Trials Evaluating Lorcaserin for the Treatment of Obesity
11. Arena Pharmaceuticals Enters Into Strategic Agreements for the Manufacture of Pharmaceutical Material, Including Lorcaserin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... This news release is available in German . ... photonic crystal around several quantum dots in a semiconductor layer. ... a consequence of atomic processes. If a short laser pulse ... modified and the quantum dot experiences a change in the ... slow down the emission of light by the dot. As ...
(Date:9/30/2014)... , Sept. 30, 2014 Pacific Northwest ... Summary Global Markets Direct,s, ,Pacific Northwest ... provides an overview of the Pacific Northwest Biotechnology, ... report provides comprehensive information on the current therapeutic ... with comparative analysis at various stages, therapeutics assessment ...
(Date:9/30/2014)... Over the last decade, the laboratory filtration market ... and increased acceptance of new filtration technologies in end ... are also catalyzing the growth of laboratory filtration market. ... grow at a strong CAGR during the forecast period ... million by 2019. The market is mainly driven by ...
(Date:9/30/2014)... 30, 2014 CORD:USE Cord Blood Bank – ... it has entered into an Equity and Exclusive Services ... licensed a series of patented technologies for the isolation of ... applications.  Tianhe is performing Phase I/II clinical trials in ... using Tianhe,s Stem Cell Educator Therapy showing ...
Breaking Biology Technology:Ultrafast remote switching of light emission 2Pacific Northwest Biotechnology, LLC - Product Pipeline Review - 2014 2Pacific Northwest Biotechnology, LLC - Product Pipeline Review - 2014 3Global Laboratory Filtration Market To See 7.0% CAGR to 2019 Says a Research Report Available at ReportsnReports.com 2Global Laboratory Filtration Market To See 7.0% CAGR to 2019 Says a Research Report Available at ReportsnReports.com 3Global Laboratory Filtration Market To See 7.0% CAGR to 2019 Says a Research Report Available at ReportsnReports.com 4Global Laboratory Filtration Market To See 7.0% CAGR to 2019 Says a Research Report Available at ReportsnReports.com 5CORD:USE is Pleased to Announce it has Partnered with Tianhe Stem Cell Biotechnologies, Developer of Cord Blood Stem Cell Therapy Showing Promising Results in Clinical Trials for the Treatment of Diabetes and Autoimmune Diseases 2CORD:USE is Pleased to Announce it has Partnered with Tianhe Stem Cell Biotechnologies, Developer of Cord Blood Stem Cell Therapy Showing Promising Results in Clinical Trials for the Treatment of Diabetes and Autoimmune Diseases 3CORD:USE is Pleased to Announce it has Partnered with Tianhe Stem Cell Biotechnologies, Developer of Cord Blood Stem Cell Therapy Showing Promising Results in Clinical Trials for the Treatment of Diabetes and Autoimmune Diseases 4
... , , WASHINGTON , Jan. 27 ... which are increasingly used for research and therapeutic interventions, but extracting ... have found evidence that fat tissue, known as adipose tissue, may ... called hematopoietic stem and progenitor cells (HSPCs), according to a ...
... , , , , , , ... Biologic,Products, Inc. (Nasdaq: CBPO ) ("China Biologic," or the "Company"), ... responded to,allegations regarding the Company, certain members of its Board of ... online,financial websites. , The article, which was ...
... Obtain Stem Cells From Embryos , WHITE PLAINS, N.Y. ... reprogrammed adult cells into embryonic-like stem cells has been chosen to receive ... Shinya Yamanaka , MD, PhD, of the Gladstone Institute of Cardiovascular Disease, ... will be honored with the 2010 March of Dimes Prize for his ...
Cached Biology Technology:Fat Tissue May Be a Source of Valuable Blood Stem Cells, Study Says 2Fat Tissue May Be a Source of Valuable Blood Stem Cells, Study Says 3Fat Tissue May Be a Source of Valuable Blood Stem Cells, Study Says 4China Biologic Products Responds to Allegations on Financial Websites 2China Biologic Products Responds to Allegations on Financial Websites 3China Biologic Products Responds to Allegations on Financial Websites 4China Biologic Products Responds to Allegations on Financial Websites 5March of Dimes Awards $250,000 Prize to Scientist Who Discovered How to Reprogram Human Cells 2
(Date:9/30/2014)... research, involving mice and published in the October 2014 ... , suggests that just because you can do ... team of Italian scientists have found that using marijuana ... immune system. This damage may result in autoimmune diseases ... bowel disease and rheumatoid arthritis in adulthood. , "I ...
(Date:9/30/2014)... MILFORD, Mass. , Sept. 30, 2014 ... process control solutions for the biotech and ... of its new RECONN Bioprocess Manager, an ... reporting solution geared towards bioprocess development laboratories. ... facilities have disparate bioreactor and analyzer systems. ...
(Date:9/29/2014)... A new study confirms that the exposure to tar ... than of regular cigarettes. Similarly, exposure to nicotine ... increasingly popular type of cigarette in several countries around ... of certain toxic chemicals in the smoke of these ... because lower levels of chemicals in the smoke are ...
Breaking Biology News(10 mins):Adolescent exposure to thc may cause immune systems to go up in smoke 2Spectra Automation Introduces RECONN Bioprocess Manager 2Slim cigarette smokers not exposed to more harmful chemicals 2
... Hall of Fame quarterback Dan Marino and VitaCore Health ... specific nutritional supplements based on authentic sciences. Marino joined ... develop health products that will strongly impact how consumers ... specifically in terms of their joints, heart, wellbeing, endurance, ...
... The stories they could tell, these fishes that once swam ... In the 1960s and ,70s, Richard Rosenblatt, a marine ... on field expeditions to remote places to study the fishes ... waters, Rosenblatt and other scientists retrieved hundreds of specimens of ...
... (BRONX, NY) Scientists at Albert Einstein ... a desktop genome analyzer and browser that allows biologists ... data. The open-source software, called GenPlay, is described in ... genomic data is analyzed mainly by information specialists rather ...
Cached Biology News:Dan Marino Teams up with VitaCore Health Products 2Dan Marino Teams up with VitaCore Health Products 3'Library of Fishes' to feature thousands of specimens from remote locations 2'Library of Fishes' to feature thousands of specimens from remote locations 3Einstein offers easy-to-use genome analyzer to scientific community 2